<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598971</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00779</org_study_id>
    <nct_id>NCT04598971</nct_id>
  </id_info>
  <brief_title>Urine pH and Urinary Tract Infection</brief_title>
  <acronym>PHURINE</acronym>
  <official_title>Consequences of UTI on Urine pH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTI) affect the urine pH and may lead to salt precipitation such as&#xD;
      struvite. Bacteria with urease activity are known to alkalinise urine, but not much is known&#xD;
      on how pH is changing over time during UTI.&#xD;
&#xD;
      This study aims at following urine pH progression at the time of diagnosis of UTI and during&#xD;
      the treatment phase.&#xD;
&#xD;
      Description of the change in urine pH over time will help understanding the risk of struvite&#xD;
      formation and potential timing of intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults presenting with UTI symptoms will be screened for infection and instructed to monitor&#xD;
      urine pH during the course of treatment and 1 week after. Urine pH will be measured by the&#xD;
      patients using calibrated pH-stix. Type of bacteria, antibiotics, and the type of diet will&#xD;
      be monitored during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine pH</measure>
    <time_frame>21 days</time_frame>
    <description>Urine pH is monitored by the patient every morning during the treatment phase and 7 days after the end of treatment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Urinary Stone</condition>
  <arm_group>
    <arm_group_label>Cystitis</arm_group_label>
    <description>Patients with lower UTI will be included in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyelonephritis</arm_group_label>
    <description>Patients with higher UTI will be included in this group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient consulting the primary care unit of the medical outpatient clinic UniSanté in&#xD;
        Lausanne will be asked to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1. Cystitis&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms of dysuria, pollakiuria, no fever AND&#xD;
&#xD;
          -  urine-stix positive for leucocytes OR positive culture (&gt;10E5 cfu/ml)&#xD;
&#xD;
        Group 2. Pyelonephritis&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral flank pain, pollakiuria, dysuria, fever (&gt;38.5°C) AND&#xD;
&#xD;
          -  urine-stix positive for leucocytes OR positive culture (&gt;10E5 cfu/ml)&#xD;
&#xD;
        Exclusion Criteria (both groups):&#xD;
&#xD;
          -  known urinary tract anatomic abnormalities&#xD;
&#xD;
          -  Presence of a urine catheter&#xD;
&#xD;
          -  Sepsis - septic shock&#xD;
&#xD;
          -  Patient taking drug interfering with urine pH (diuretics, citrate, acetazolamide,&#xD;
             topiramate,...)&#xD;
&#xD;
          -  Patients with UTI diagnosed in the preceding month&#xD;
&#xD;
          -  Patients having received antibiotics during the preceding month&#xD;
&#xD;
          -  Male patient with a diagnosis of prostatitis&#xD;
&#xD;
          -  Presence of infected kidney cyst&#xD;
&#xD;
          -  Patient with diabetes&#xD;
&#xD;
          -  Pregnant female&#xD;
&#xD;
          -  Patient with obstructive pyelonephritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Olivier Bonny, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV-Lausanne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Desponds, BM</last_name>
    <phone>+41795561934</phone>
    <email>Charlotte.Desponds@unil.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Gouveia, MD</last_name>
    <email>Alexandre.Gouveia@unisante.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UniSanté</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Gouveia, MD</last_name>
      <phone>+41213144905</phone>
      <email>Alexandre.Gouveia@unisant.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Olivier Bonny</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>urine pH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

